Clinical trials

  • AZD4512 for B-cell non-Hodgkin lymphoma (relapsed/refractory)
  • SPESOLIMAB for Pyoderma gangrenosum
  • DEMERECVIRIDAE BACTERIOPHAGE AGAINST KLEBESIELLA PNEUMONIAE (113.073 BP), DREXLERVIRIDAE BACTERIOPHAGE AGAINST KLEBESIELLA PNEUMONIAE (45.423 BP), MYOVIRIDAE BACTERIOPHAGE AGAINST KLEBESIELLA PNEUMONIAE (169.802 BP), MYOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (65.855 BP), MYOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (92.792 BP), SIPHOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (43.020 BP) for Ventilator-associated pneumonia
  • pembrolizumab for Non-squamous non-small cell lung cancer (advanced or metastatic)
  • DNAJB1-PRKACA TRIFLUORACETATE for Fibrolamellar hepatocellular carcinoma|Tumors carrying DNAJB1-PRKACA fusion
  • ITI-1284 for Agitation associated with Alzheimer's dementia | Alzheimer's disease
  • CAPECITABINE for Colon cancer
  • Etoposide phosphate for Primary central nervous system lymphoma | Relapsed or refractory primary central nervous system lymphoma
  • RITUXIMAB for Multiple sclerosis
  • OCRELIZUMAB for Multiple sclerosis
  • LIDOCAINE HYDROCHLORIDE MONOHYDRATE for Subarachnoid hemorrhage
  • sorafenib for Hepatocellular carcinoma | Renal cell carcinoma | Differentiated thyroid carcinoma